HeartSciences Inc(HSCS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HSCS HeartSciences Inc

Market Closed 01-23 16:00:00 EST

3.45

+0.00

0.00%

盘后3.45

+0.000.00%

19:51 EST

High3.55	Low3.45	Vol14.61K
Open3.45	D1 Closing3.45	Amplitude2.96%
Mkt Cap10.96M	Tradable Cap10.55M	Total Shares3.18M
T/O51.02K	T/O Rate0.48%	Tradable Shares3.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HSCS","market":"US","secType":"STK","nameCN":"HeartSciences Inc","latestPrice":3.45,"timestamp":1769202000000,"preClose":3.45,"halted":0,"volume":14609,"hourTrading":{"tag":"盘后","latestPrice":3.45,"preClose":3.45,"latestTime":"19:51 EST","volume":23,"amount":81.25,"timestamp":1769215873309,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":3059200,"shares":3178207,"eps":-6.8747,"marketStatus":"Market Closed","change":0,"latestTime":"01-23 16:00:00 EST","open":3.45,"high":3.552,"low":3.45,"amount":51022.550460700004,"amplitude":0.029565,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.8747,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1655265600000,"exchange":"NASDAQ","adjPreClose":3.45,"preHourTrading":{"tag":"盘前","latestPrice":3.41,"preClose":3.45,"latestTime":"08:45 EST","volume":27,"amount":98.2300041,"timestamp":1769175911680,"change":-0.04,"changeRate":-0.011594,"amplitude":0.081159},"postHourTrading":{"tag":"盘后","latestPrice":3.45,"preClose":3.45,"latestTime":"19:51 EST","volume":23,"amount":81.25,"timestamp":1769215873309,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.2905771756019942},"requestUrl":"/m/hq/s/HSCS/wiki","defaultTab":"wiki","newsList":[{"id":"2604380914","title":"HeartSciences Secures $3.6 Million Unsecured Loan from Streeterville Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2604380914","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604380914?lang=en_us&edition=fundamental","pubTime":"2026-01-17 06:16","pubTimestamp":1768601767,"startTime":"0","endTime":"0","summary":"HeartSciences Inc. has entered into a new financing agreement with Streeterville Capital, LLC, an institutional investor. Under the Note Purchase Agreement signed on January 13, 2026, Streeterville purchased an unsecured promissory note from HeartSciences valued at $3,605,000. This amount includes an original issue discount of $600,000 and reimbursement of $5,000 in transaction expenses, resulting in gross proceeds of $3,000,000 to HeartSciences. The agreement contains customary covenants, representations, warranties, and events of default, including provisions that accelerate repayment if the company undergoes certain fundamental transactions without Streeterville's consent. The agreement also provides for indemnification of Streeterville in the event of breaches by HeartSciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL9TK38r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HSCS"],"gpt_icon":0},{"id":"2593848911","title":"HeartSciences Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2593848911","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593848911?lang=en_us&edition=fundamental","pubTime":"2025-12-22 18:48","pubTimestamp":1766400480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HSCS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 05:48 ET (10:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2591246756","title":"Heart Test Laboratories Q2 EPS $(0.85) Beats $(1.69) Estimate, Sales $2.419M Beat $50.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2591246756","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591246756?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:20","pubTimestamp":1765833603,"startTime":"0","endTime":"0","summary":"Heart Test Laboratories Q2 EPS $(0.85) Beats $(1.69) Estimate, Sales $2.419M Beat $50.000K Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49407253/heart-test-laboratories-q2-eps-0-85-beats-1-69-estimate-sales-2-419m-beat-50-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Heart Test Laboratories Q2 EPS $(0.85) Beats $(1.69) Estimate, Sales $2.419M Beat $50.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HSCS"],"gpt_icon":0},{"id":"2591243446","title":"HeartSciences Inc. reports no meaningful revenue and cash of USD 2.0 million for Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2591243446","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591243446?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:15","pubTimestamp":1765833323,"startTime":"0","endTime":"0","summary":"HeartSciences Inc. reported its financial results for the fiscal second quarter ended October 31, 2025. The company reported no meaningful revenue for Q2 2026. As of October 31, 2025, HeartSciences Inc. had approximately USD 2.0 million in cash and cash equivalents and USD 4.2 million in shareholders' equity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL9Gsr36:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","SG9999014021.USD","HSCS","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","BK4082","NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","BK4112","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2591641620","title":"HeartSciences Submits MyoVista wavECG Device for FDA 510(k) Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641620","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641620?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:30","pubTimestamp":1765805438,"startTime":"0","endTime":"0","summary":"HeartSciences Inc. has submitted its MyoVista wavECG device to the U.S. Food and Drug Administration  for 510 premarket clearance. The device is designed to offer conventional ECG functionality and serve as a platform for AI-ECG algorithms. The FDA submission marks a significant regulatory milestone for the company as it continues its commercialization efforts. The company has chosen to submit the device and its associated AI-ECG software algorithm separately to simplify the regulatory process and accelerate device clearance. No grant or funding involving HeartSciences Inc. is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via GlobeNewswire  o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL9CsgMh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","HSCS","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","NDAQ","BK4588","BK4082","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2591641603","title":"Heartsciences Announces FDA 510(K) Submission for Myovista® Wavecg™ Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641603?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:30","pubTimestamp":1765805400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA7QYFQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HSCSW","HSCS","BK4082"],"gpt_icon":0},{"id":"2587730799","title":"Heartsciences Inc. Announces Unregistered Sale of Equity Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2587730799","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587730799?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:10","pubTimestamp":1764367855,"startTime":"0","endTime":"0","summary":"Heartsciences Inc. has announced the unregistered sale of equity securities in connection with amendments to its 2023 Equity Incentive Plan. The company's Board of Directors approved an increase in the maximum aggregate number of shares issuable under the plan to 1,250,000 shares of common stock, with an annual automatic increase provision beginning in fiscal year 2026. Equity awards, including restricted shares and restricted stock units, were granted to executive officers, non-employee directors, and employees. The offering and issuance of these equity awards are exempt from registration under Section 4 of the Securities Act of 1933, Rule 506 of Regulation D, and/or Rule 701 and applicable state securities laws. The plan amendment is subject to shareholder approval at the next annual meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDLbrg3zQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2572568741","title":"BRIEF-HeartSciences Enters Amendment No. 7 To Loan Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572568741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572568741?lang=en_us&edition=fundamental","pubTime":"2025-10-02 05:31","pubTimestamp":1759354296,"startTime":"0","endTime":"0","summary":"BRIEF-HeartSciences Enters Amendment No. 7 To Loan Agreement - SEC FilingOct 1 (Reuters) - HeartSciences Inc HSCS.O:HEARTSCIENCES INC - ENTERS AMENDMENT NO. 7 TO LOAN AGREEMENT - SEC FILINGHEARTSCIENC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nFWN3VI162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HSCS"],"gpt_icon":0},{"id":"2572568498","title":"Heartsciences Inc - Maturity Date of Note Extended to September 30, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572568498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572568498?lang=en_us&edition=fundamental","pubTime":"2025-10-02 05:24","pubTimestamp":1759353885,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nFWN3VI162:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","HSCS"],"gpt_icon":0},{"id":"2572568493","title":"Heartsciences Inc - Enters Amendment No. 7 to Loan Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572568493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572568493?lang=en_us&edition=fundamental","pubTime":"2025-10-02 05:24","pubTimestamp":1759353885,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nFWN3VI162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2572684955","title":"HeartSciences Inc. Extends Loan Maturity to 2026 in Amended Financing Agreement with Front Range Ventures","url":"https://stock-news.laohu8.com/highlight/detail?id=2572684955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572684955?lang=en_us&edition=fundamental","pubTime":"2025-10-02 05:24","pubTimestamp":1759353859,"startTime":"0","endTime":"0","summary":"**HeartSciences Inc. Extends Loan Maturity Date with Front Range Ventures** HeartSciences Inc. announced it has entered into Amendment No. 7 to its existing Loan and Security Agreement with Front Range Ventures LLC , further extending the maturity date of its $500,000 secured promissory note. Under the new terms, the maturity date has been pushed back to September 30, 2026. HeartSciences will pay all accrued unpaid interest as of September 30, 2025, by that date, with any subsequent interest due at maturity. The company also retains the option to repay any or all of the outstanding principal, with a minimum repayment of $50,000, at any time before the new maturity date. The note continues to bear interest at 12% per annum, compounded annually.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL5HcbM0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2572960538","title":"HeartSciences Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2572960538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572960538?lang=en_us&edition=fundamental","pubTime":"2025-10-01 18:36","pubTimestamp":1759314960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HSCS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 01, 2025 06:36 ET (10:36 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HSCS"],"gpt_icon":0},{"id":"2566919790","title":"Heartsciences Inc - Reports No Meaningful Revenue for Fq1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2566919790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566919790?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:25","pubTimestamp":1757622304,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nFWN3UY13F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HSCSW","BK4082","HSCS"],"gpt_icon":0},{"id":"2566919121","title":"Heart Test Laboratories Q1 EPS $(1.58) Beats $(2.09) Estimate, Sales $1.900M","url":"https://stock-news.laohu8.com/highlight/detail?id=2566919121","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566919121?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:19","pubTimestamp":1757621960,"startTime":"0","endTime":"0","summary":"Heart Test Laboratories (NASDAQ:HSCS) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(2.09) by 24.4 percent. This is a 40.15 percent increase over losses of $(2.64) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47632255/heart-test-laboratories-q1-eps-1-58-beats-2-09-estimate-sales-1-900m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Heart Test Laboratories Q1 EPS $(1.58) Beats $(2.09) Estimate, Sales $1.900M","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS"],"gpt_icon":0},{"id":"2566919515","title":"Heartsciences Inc. Reports Minimal Revenues for Q3 2025; Research and Development Expenses Decrease by 19% Compared to Q3 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2566919515","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566919515?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:06","pubTimestamp":1757621174,"startTime":"0","endTime":"0","summary":"Heartsciences Inc. Reports Minimal Revenues for Q3 2025; Research and Development Expenses Decrease by 19% Compared to Q3 2024. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL4vmlJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS"],"gpt_icon":0},{"id":"2565500317","title":"Heartsciences Inc. Announces Conversion of Preferred Shares and Debt Exchange, Issuing Over 2.6 Million Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500317","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500317?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:02","pubTimestamp":1757325765,"startTime":"0","endTime":"0","summary":"Heartsciences Inc. Announces Conversion of Preferred Shares and Debt Exchange, Issuing Over 2.6 Million Shares of Common Stock. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDLbgSpgX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2561400646","title":"HeartSciences Inc. Announces Conversion of Preferred Shares and Debt Exchange, Reducing Principal by $1.65 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2561400646","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561400646?lang=en_us&edition=fundamental","pubTime":"2025-08-23 04:10","pubTimestamp":1755893402,"startTime":"0","endTime":"0","summary":"Heartsciences Inc. has announced a significant financial maneuver involving the conversion of preferred shares and a debt exchange. As of August 22, 2025, the company has successfully converted 979,851 shares of its Series D Preferred Stock into an equal number of common stock shares. Additionally, Heartsciences has executed a debt exchange, converting $1,655,000 of an unsecured promissory note into 461,572 shares of common stock. These strategic moves have increased the total number of outstanding common stock shares to 2,535,066. This development reflects Heartsciences' ongoing efforts to streamline its capital structure and bolster its financial standing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDLcfy7RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2556381124","title":"Heartsciences Inc. Expands Equity Distribution Agreement to Sell Up to $25M in Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2556381124","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556381124?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:31","pubTimestamp":1754310684,"startTime":"0","endTime":"0","summary":"Heartsciences Inc. has entered into an Equity Distribution Agreement with Maxim Group LLC, allowing the company to offer and sell up to $25,000,000 of its common stock. Under the agreement, Maxim Group will act as the sales agent. The company has not sold any shares under this agreement as of the latest report. The commission rates are set at 4.0% for sales up to $11,036,310 in gross proceeds and 3.0% for amounts exceeding that. The current market value of the company's outstanding shares held by non-affiliates is $14,737,609, based on 2,276,253 shares at a price of $5.73 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL7n03WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2555075441","title":"Mark Hilz, COO and Director, Reports Disposal of Common Shares in HeartSciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2555075441","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555075441?lang=en_us&edition=fundamental","pubTime":"2025-07-31 09:00","pubTimestamp":1753923638,"startTime":"0","endTime":"0","summary":"Mark Hilz, COO, Secretary, and Director of HeartSciences Inc., reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDLbg4xpt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCS","BK4082"],"gpt_icon":0},{"id":"2555022508","title":"HeartSciences Inc. Announces Conversion of Preferred Shares and Debt Exchange to Strengthen Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2555022508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555022508?lang=en_us&edition=fundamental","pubTime":"2025-07-31 04:39","pubTimestamp":1753907995,"startTime":"0","endTime":"0","summary":"HeartSciences Inc. has announced significant financial developments as of July 29, 2025. The company successfully converted $1,105,000 of an unsecured promissory note issued in September 2024 into 301,111 shares of common stock, effectively reducing the principal amount of the note. Additionally, as part of their ongoing Regulation A Offering, a total of $4.3 million in gross proceeds has been received, leading to the issuance of 1,241,188 units. Notably, holders of 850,981 shares of Series D Preferred Stock opted to convert their shares into an equivalent number of common stock shares. These actions have resulted in a total of 2,244,247 shares of common stock issued and outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDLPmPq5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HSCS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.heartsciences.com","stockEarnings":[{"period":"1week","weight":0.0781},{"period":"1month","weight":0.3372},{"period":"3month","weight":0.0486},{"period":"6month","weight":-0.1244},{"period":"1year","weight":0},{"period":"ytd","weight":0.1165}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Heart Test Laboratories, Inc., doing business as HeartSciences, is a medical technology company focuses on applying AI-based technology to an ECG to expand and improve an ECG's clinical utility. It is developing AI-ECG solutions to be made available on a hardware agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is designed to provide diagnostic information related to cardiac dysfunction. The MyoVista also provides conventional ECG information in the same test. The company was incorporated in 2007 and is headquartered in Southlake, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.34635},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.157939},{"month":3,"riseRate":0,"avgChangeRate":-0.163817},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.022495},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.090109},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.028659},{"month":7,"riseRate":0,"avgChangeRate":-0.166158},{"month":8,"riseRate":0.25,"avgChangeRate":-0.062054},{"month":9,"riseRate":0.5,"avgChangeRate":-0.034053},{"month":10,"riseRate":0.25,"avgChangeRate":0.034909},{"month":11,"riseRate":0.25,"avgChangeRate":-0.161956},{"month":12,"riseRate":0.5,"avgChangeRate":-0.039261}],"exchange":"NASDAQ","name":"HeartSciences Inc","nameEN":"HeartSciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HeartSciences Inc(HSCS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HeartSciences Inc(HSCS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HeartSciences Inc,HSCS,HeartSciences Inc股票,HeartSciences Inc股票老虎,HeartSciences Inc股票老虎国际,HeartSciences Inc行情,HeartSciences Inc股票行情,HeartSciences Inc股价,HeartSciences Inc股市,HeartSciences Inc股票价格,HeartSciences Inc股票交易,HeartSciences Inc股票购买,HeartSciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HeartSciences Inc(HSCS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HeartSciences Inc(HSCS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction